Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 59.81 | 59.82 | 67.82 | 92.51 | 71.63 | 72.26 | 103.98 | 116.00 | 64.62 | 65.19 | 99.62 | 93.74 |
| Expenses | 55.49 | 53.21 | 66.82 | 88.02 | 79.29 | 68.62 | 101.75 | 102.22 | 63.79 | 63.45 | 100.14 | 85.21 |
| Operating Profit | 4.32 | 6.61 | 1.00 | 4.49 | -7.66 | 3.64 | 2.23 | 13.78 | 0.83 | 1.74 | -0.52 | 8.53 |
| OPM % | 7.22% | 11.05% | 1.47% | 4.85% | -10.69% | 5.04% | 2.14% | 11.88% | 1.28% | 2.67% | -0.52% | 9.10% |
| Other Income | 2.60 | 1.26 | 2.64 | 2.54 | 4.21 | 2.94 | 1.93 | 1.06 | 3.53 | 1.33 | 3.63 | 1.11 |
| Interest | 0.63 | 0.58 | 1.13 | 2.77 | 2.91 | 3.33 | 3.94 | 3.69 | 3.11 | 2.90 | 2.85 | 2.45 |
| Depreciation | 1.75 | 1.82 | 3.87 | 9.03 | 9.01 | 8.76 | 8.52 | 8.60 | 8.56 | 8.46 | 8.63 | 8.69 |
| Profit before tax | 4.54 | 5.47 | -1.36 | -4.77 | -15.37 | -5.51 | -8.30 | 2.55 | -7.31 | -8.29 | -8.37 | -1.50 |
| Tax % | 46.48% | 33.46% | 88.24% | 85.32% | 13.92% | 43.01% | 13.61% | 133.73% | 17.65% | 16.77% | -2.51% | 138.00% |
| Net Profit | 2.43 | 3.64 | -2.56 | -8.84 | -17.51 | -7.88 | -9.44 | -0.87 | -8.60 | -9.67 | -8.16 | -3.56 |
| EPS in Rs | 6.05 | 6.50 | -0.52 | 1.96 | -11.50 | -2.42 | -6.86 | 11.94 | -10.49 | -6.37 | -6.96 | 1.47 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 124 | 111 | 137 | 220 | 228 | 205 | 212 | 218 | 261 | 340 | 345 | 323 |
| Expenses | 114 | 105 | 124 | 191 | 200 | 179 | 183 | 198 | 234 | 337 | 330 | 313 |
| Operating Profit | 10 | 7 | 12 | 29 | 28 | 25 | 29 | 20 | 27 | 4 | 16 | 11 |
| OPM % | 8% | 6% | 9% | 13% | 12% | 12% | 14% | 9% | 10% | 1.1% | 4.6% | 3.3% |
| Other Income | 5 | 8 | 7 | 13 | 11 | 9 | 7 | 12 | 5 | 11 | 10 | 10 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 13 | 13 | 11 |
| Depreciation | 4 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 9 | 35 | 34 | 34 |
| Profit before tax | 9 | 7 | 13 | 35 | 33 | 27 | 28 | 24 | 19 | -34 | -21 | -25 |
| Tax % | 31% | 8% | 29% | 39% | 26% | 25% | 25% | 33% | 44% | 29% | 27% | |
| Net Profit | 6 | 7 | 9 | 21 | 24 | 20 | 21 | 16 | 11 | -44 | -27 | -30 |
| EPS in Rs | 11.26 | 12.03 | 15.92 | 37.09 | 42.13 | 35.59 | 36.45 | 28.47 | 24.95 | -18.33 | -11.88 | -22.35 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 4% | -5% | -8% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 11% | 11% | 17% | -11% | ||
| Compounded Profit Growth | % | % | % | -172% | ||
| Stock Price CAGR | % | 39% | 52% | 54% | ||
| Return on Equity | 7% | 3% | -1% | -3% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 |
| Reserves | 51 | 58 | 67 | 88 | 112 | 138 | 160 | 177 | 191 | 324 | 315 |
| Borrowings | 19 | 6 | 9 | 5 | 1 | 12 | 18 | 50 | 158 | 180 | 146 |
| Other Liabilities | 44 | 40 | 50 | 60 | 68 | 43 | 42 | 118 | 149 | 138 | 145 |
| Total Liabilities | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 504 | 649 | 613 |
| Fixed Assets | 35 | 31 | 34 | 35 | 33 | 45 | 41 | 42 | 211 | 252 | 255 |
| CWIP | 0 | 0 | 0 | 1 | 12 | 0 | 26 | 99 | 25 | 31 | 35 |
| Investments | 0 | 1 | 1 | 1 | 0 | 43 | 11 | 0 | 0 | 5 | 6 |
| Other Assets | 85 | 79 | 98 | 121 | 142 | 111 | 148 | 209 | 268 | 360 | 317 |
| Total Assets | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 504 | 649 | 613 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | -2 | 6 | 20 | 14 | 24 | -1 | 22 | -5 | -27 | 38 |
| Cash from Investing Activity | 0 | -2 | -8 | -9 | -13 | -43 | -7 | -78 | -105 | -137 | 9 |
| Cash from Financing Activity | 0 | -8 | 4 | -4 | -3 | 10 | 9 | 61 | 110 | 156 | -47 |
| Net Cash Flow | 0 | -11 | 2 | 7 | -1 | -8 | 2 | 4 | 1 | -8 | 1 |
| Free Cash Flow | 0 | -4 | -2 | 12 | -0 | 24 | -40 | -68 | -108 | -56 | -1 |
| CFO/OP | 0% | -8% | 73% | 107% | 87% | 123% | 16% | 150% | 18% | -444% | 305% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 130 | 143 | 157 | 106 | 127 | 121 | 126 | 188 | 198 | 184 | 159 |
| Inventory Days | 62 | 70 | 60 | 59 | 71 | 61 | 56 | 100 | 142 | 132 | 162 |
| Days Payable | 171 | 168 | 110 | 83 | 104 | 71 | 64 | 136 | 137 | 136 | 122 |
| Cash Conversion Cycle | 21 | 45 | 107 | 82 | 93 | 111 | 118 | 152 | 202 | 180 | 199 |
| Working Capital Days | 8 | 64 | 78 | 73 | 89 | 106 | 148 | 91 | 81 | 76 | 143 |
| ROCE % | 11% | 18% | 39% | 31% | 20% | 17% | 11% | 7% | -4% | -2% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 73.84% | 73.84% | 73.27% | 73.27% | 65.35% | 67.20% | 67.20% | 67.19% | 67.19% | 67.19% | 67.17% | 67.20% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.08% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
| DIIs | 0.01% | 0.01% | 0.01% | 0.01% | 0.57% | 0.54% | 0.54% | 0.54% | 0.54% | 0.54% | 1.07% | 1.38% |
| Public | 26.15% | 26.15% | 26.72% | 26.72% | 33.98% | 32.16% | 32.15% | 32.16% | 32.16% | 32.17% | 31.65% | 31.31% |
| No. of Shareholders | 2,481 | 2,397 | 2,497 | 2,708 | 2,748 | 3,116 | 3,177 | 3,231 | 3,205 | 3,172 | 3,095 | 3,059 |
Fundamentals
Market Cap₹ 1,335 Cr.
Current Price₹ 1,926
Book Value₹ 468
ROCE-1.87 %
ROE-2.54 %
Dividend Yield0.05 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-11%
Compounded Profit Growth (TTM)-172%
Consolidated figures.
Valuation
Market capRs 1,186 Cr
Enterprise valueRs 1,320 Cr
Price to book3.68x
Price to sales3.67x
EV / EBITDA65.41x
EV / sales4.08x
Price to cash flow30.91x
Earnings yield-1.30%
Dividend yield0.06%
P/E, 3-year average44.98x
P/B, 3-year average2.43x
P/E, 5-year average22.05x
P/B, 5-year average1.91x
Profitability
Operating margin (excl. other income)4.58%
Operating margin (incl. other income)7.34%
EBITDA margin6.24%
Pre-tax margin-7.88%
Net profit margin-4.77%
Net margin, latest quarter1.08%
ROE-2.51%
ROCE-1.82%
ROA-1.30%
ROE, 3-year average0.12%
ROCE, 3-year average0.36%
ROA, 3-year average-0.03%
ROE, 5-year average4.67%
ROCE, 5-year average6.17%
ROA, 5-year average3.11%
ROIC (approx.)-3.95%
Tax rate-27.45%
Other income / net worth2.96%
Growth
Sales growth (latest year)1.48%
Sales CAGR, 3 years16.59%
Sales CAGR, 5 years11.04%
Sales growth QoQ-5.90%
Sales growth YoY (latest quarter)-19.19%
Profit growth YoY (latest quarter)-87.73%
Per share
EPS (TTM)Rs -22.36
EPS (latest year)Rs -11.88
EPS (latest quarter)Rs 1.47
EPS, 3-year averageRs -1.75
EPS, 5-year averageRs 11.93
Book value per shareRs 467.54
Sales per shareRs 468.91
Cash flow per shareRs 55.66
Free cash flow per shareRs -1.45
Dividend per share (latest year)Rs 1.00
Dividend per share, 3-year averageRs 1.00
Dividend per share, 5-year averageRs 0.94
Dividends
Dividend payout, 3-year average3.99%
Dividend payout, 5-year average3.31%
Efficiency
Asset turnover0.56x
Fixed asset turnover1.36x
Inventory turnover2.62x
Inventory days139 days
Debtor days159 days
Debtors turnover2.29x
Creditor days122 days
Cash conversion cycle199 days
Working capital days143 days
Leverage
Total debtRs 146 Cr
Cash and bankRs 12 Cr
Net debtRs 134 Cr
Debt to equity0.45x
Net debt / EBITDA6.65x
Interest coverage-1.25x
Owners' fund to total sources52.54%
Debt to assets23.82%
Cash flow
Cash from Operating Activity (latest year)Rs 38 Cr
Cash from Investing Activity (latest year)Rs 9 Cr
Cash from Financing Activity (latest year)Rs -47 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs -1 Cr
FCFE (approx.: FCF + change in debt)Rs -35 Cr
Sales to cash flow9.01x
Statement figures
Net sales (TTM)Rs 323 Cr
Net sales (latest year)Rs 345 Cr
Sales (latest quarter)Rs 94 Cr
Operating profit excl. other income (latest year)Rs 16 Cr
Operating profit (latest quarter)Rs 9 Cr
Other income (TTM)Rs 10 Cr
EBITDA (TTM)Rs 20 Cr
PBDT (TTM)Rs 9 Cr
Profit before tax (TTM)Rs -25 Cr
Tax (latest year)Rs 6 Cr
Net profit (TTM)Rs -15 Cr
Net profit (latest year)Rs -8 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 34 Cr
Depreciation (latest quarter)Rs 9 Cr
Interest (TTM)Rs 11 Cr
Cost of goods sold (latest year)Rs 222 Cr
Total expenditure (latest year)Rs 330 Cr
Total income (latest year)Rs 355 Cr
Share capitalRs 7 Cr
ReservesRs 315 Cr
Shareholders' fundsRs 322 Cr
Total assetsRs 613 Cr
Net blockRs 255 Cr
Capital work in progressRs 35 Cr
InvestmentsRs 6 Cr
ReceivablesRs 151 Cr
InventoryRs 85 Cr
Other liabilitiesRs 145 Cr
Shares outstanding (crore)0.69
Ownership
Promoter holding67.20% (+0.01 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 3.68 is at the 86th percentile (median 2.06).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | BPLPHARMA | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +8.8% | -2.8% | +11.5 pts |
| 1 month | +14.1% | -6.8% | +20.9 pts |
| 3 years | +214.5% | +14.2% | +200.3 pts |
| 5 years | +355.3% | +27.9% | +327.4 pts |
1 mutual fund schemes hold about ₹0 Cr.
Over three months 0 bought more and 0 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| WOC Pharma and Healthcare Fund | 0.04% | 0 |
Red flags
F-score 7 of 8| look | Repeated losses Net loss in each of the last two years |
| look | On NSE surveillance On NSE surveillance: ASM short-term |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹94 Cr -19.2% vs Jun 2025.
Net loss ₹4 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-09-11 | Dividend - Re 1 Per Share |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Short Term Additional Surveillance Measure (Short Term ASM): stage 1